https://investors.atarabio.com/ https://investors.atarabio.com/news-events https://investors.atarabio.com/news-events/press-releases https://investors.atarabio.com/news-events/events https://investors.atarabio.com/news-events/presentations https://investors.atarabio.com/news-events/email-alerts https://investors.atarabio.com/news-events/investor-media-contacts https://investors.atarabio.com/financial-results https://investors.atarabio.com/financial-results/financial-results https://investors.atarabio.com/financial-results/income-statement https://investors.atarabio.com/financial-results/balance-sheet https://investors.atarabio.com/financial-results/cash-flow https://investors.atarabio.com/atra-stock https://investors.atarabio.com/atra-stock/charts https://investors.atarabio.com/atra-stock/historical-data https://investors.atarabio.com/atra-stock/faq https://investors.atarabio.com/atra-stock/classification-info https://investors.atarabio.com/analyst-coverage https://investors.atarabio.com/sec-filings https://investors.atarabio.com/sec-filings/all-sec-filings https://investors.atarabio.com/sec-filings/annual-reports https://investors.atarabio.com/sec-filings/quarterly-reports https://investors.atarabio.com/sec-filings/section-16-filings https://investors.atarabio.com/governance https://investors.atarabio.comhttps://www.atarabio.com/company/board-of-directors/ https://investors.atarabio.com/governance/board-committees https://investors.atarabio.com/governance/governance-documents https://investors.atarabio.com/governance/contact-the-board https://investors.atarabio.com/news-events/press-releases/detail/384/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/383/atara-biotherapeutics-provides-regulatory-update-on https://investors.atarabio.com/news-events/press-releases/detail/382/atara-biotherapeutics-provides-regulatory-update-on https://investors.atarabio.com/news-events/press-releases/detail/381/atara-biotherapeutics-provides-a-business-update https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business https://investors.atarabio.com/news-events/press-releases/detail/379/atara-biotherapeutics-announces-third-quarter-financial https://investors.atarabio.com/news-events/press-releases/detail/378/atara-biotherapeutics-announces-changes-to-its-board-of https://investors.atarabio.com/news-events/press-releases/detail/377/atara-biotherapeutics-announces-second-quarter-financial https://investors.atarabio.com/news-events/press-releases/detail/376/atara-biotherapeutics-announces-u-s-fda-acceptance-and https://investors.atarabio.com/news-events/press-releases/detail/375/atara-biotherapeutics-provides-regulatory-and-business https://investors.atarabio.com/news-events/press-releases/detail/374/atara-biotherapeutics-appoints-james-huang-and-nachi https://investors.atarabio.com/news-events/press-releases/detail/373/atara-biotherapeutics-announces-first-quarter-financial https://investors.atarabio.com/news-events/press-releases/detail/372/atara-biotherapeutics-announces-pricing-of-16million https://investors.atarabio.com/news-events/press-releases/detail/371/atara-biotherapeutics-provides-regulatory-updates-on https://investors.atarabio.com/news-events/press-releases/detail/370/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/369/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/368/atara-biotherapeutics-provides-update-on-clinical-programs https://investors.atarabio.com/news-events/press-releases/detail/367/atara-biotherapeutics-provides-regulatory-and-business https://investors.atarabio.com/news-events/press-releases/detail/366/atara-biotherapeutics-to-participate-at-the-7th-annual https://investors.atarabio.com/news-events/press-releases/detail/365/atara-biotherapeutics-to-participate-at-the-stifel-2024 https://investors.atarabio.com/news-events/press-releases/detail/364/atara-biotherapeutics-announces-third-quarter-2024 https://investors.atarabio.com/news-events/press-releases/detail/363/atara-biotherapeutics-to-announce-third-quarter-2024 https://investors.atarabio.com/news-events/press-releases/detail/362/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/361/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/360/atara-biotherapeutics-to-participate-in-the-h-c-wainwright https://investors.atarabio.com/news-events/press-releases/detail/359/atara-biotherapeutics-announces-36-million-registered https://investors.atarabio.com/news-events/press-releases/detail/358/atara-biotherapeutics-announces-second-quarter-2024 https://investors.atarabio.com/news-events/press-releases/detail/357/atara-biotherapeutics-to-participate-in-the-canaccord https://investors.atarabio.com/news-events/press-releases/detail/356/atara-biotherapeutics-announces-u-s-fda-acceptance-and https://investors.atarabio.com/news-events/press-releases/detail/355/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/354/atara-biotherapeutics-to-participate-at-the-stifel-virtual https://investors.atarabio.com/news-events/press-releases/detail/353/atara-biotherapeutics-ebvallo-tabelecleucel-wins https://investors.atarabio.com/news-events/press-releases/detail/352/atara-biotherapeutics-announces-1-for-25-reverse-stock-split https://investors.atarabio.com/news-events/press-releases/detail/351/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/350/atara-biotherapeutics-to-participate-in-the-goldman-sachs https://investors.atarabio.com/news-events/press-releases/detail/349/atara-biotherapeutics-presents-preclinical-data-on-ata3219 https://investors.atarabio.com/news-events/press-releases/detail/348/atara-biotherapeutics-submits-tabelecleucel-tab-cel https://investors.atarabio.com/news-events/press-releases/detail/347/atara-biotherapeutics-announces-first-quarter-2024 https://investors.atarabio.com/news-events/press-releases/detail/346/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/345/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/344/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/343/atara-biotherapeutics-receives-fda-clearance-of-ind https://investors.atarabio.com/news-events/press-releases/detail/342/atara-biotherapeutics-to-participate-in-cell-therapy-panel https://investors.atarabio.com/news-events/press-releases/detail/341/atara-biotherapeutics-announces-submission-of https://investors.atarabio.com/news-events/press-releases/detail/340/atara-biotherapeutics-and-pierre-fabre-laboratories https://investors.atarabio.com/news-events/press-releases/detail/339/atara-biotherapeutics-announces-15-million-registered https://investors.atarabio.com/news-events/press-releases/detail/338/atara-biotherapeutics-to-present-recent-progress-and-key https://investors.atarabio.com/news-events/press-releases/detail/337/atara-biotherapeutics-to-present-at-the-42nd-annual-j-p https://investors.atarabio.com/news-events/press-releases/detail/336/atara-biotherapeutics-announces-closing-of-expanded-global https://investors.atarabio.com/news-events/press-releases/detail/335/atara-biotherapeutics-presents-positive-preclinical-data-on https://investors.atarabio.com/news-events/press-releases/detail/334/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/333/atara-biotherapeutics-to-present-positive-new-tab-cel https://investors.atarabio.com/news-events/press-releases/detail/332/atara-biotherapeutics-to-participate-at-the-6th-annual https://investors.atarabio.com/news-events/press-releases/detail/331/atara-biotherapeutics-to-participate-at-the-stifel https://investors.atarabio.com/news-events/press-releases/detail/330/atara-biotherapeutics-announces-primary-analysis-data-from https://investors.atarabio.com/news-events/press-releases/detail/329/atara-biotherapeutics-announces-expanded-global-tab-cel https://investors.atarabio.com/news-events/press-releases/detail/328/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/327/atara-biotherapeutics-announces-plans-to-submit-tab-cel https://investors.atarabio.com/news-events/press-releases/detail/326/atara-biotherapeutics-inc-reports-inducement-grant-under https://investors.atarabio.com/news-events/press-releases/detail/325/atara-biotherapeutics-to-participate-in-cell-therapies-in https://investors.atarabio.com/news-events/press-releases/detail/324/atara-biotherapeutics-announces-second-quarter-2023 https://investors.atarabio.com/news-events/press-releases/detail/323/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/322/atara-biotherapeutics-to-announce-second-quarter-2023 https://investors.atarabio.com/news-events/press-releases/detail/321/atara-biotherapeutics-to-participate-in-the-canaccord https://investors.atarabio.com/news-events/press-releases/detail/320/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/319/atara-biotherapeutics-to-participate-in-the-goldman-sachs https://investors.atarabio.com/news-events/press-releases/detail/318/atara-biotherapeutics-presents-updated-tab-cel-clinical https://investors.atarabio.com/news-events/press-releases/detail/317/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/316/atara-biotherapeutics-announces-first-quarter-2023 https://investors.atarabio.com/news-events/press-releases/detail/315/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/314/atara-biotherapeutics-to-announce-first-quarter-2023 https://investors.atarabio.com/news-events/press-releases/detail/313/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/312/atara-biotherapeutics-inc-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/311/atara-biotherapeutics-to-participate-in-cell-therapy-panel https://investors.atarabio.com/news-events/press-releases/detail/310/atara-biotherapeutics-to-participate-in-the-h-c-wainwright https://investors.atarabio.com/news-events/press-releases/detail/309/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/308/pierre-fabre-to-commercialize-and-distribute-the-first https://investors.atarabio.com/news-events/press-releases/detail/307/atara-biotherapeutics-to-announce-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/306/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/305/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/304/atara-biotherapeutics-to-present-at-the-41st-annual-j-p https://investors.atarabio.com/news-events/press-releases/detail/303/atara-biotherapeutics-announces-31-million-royalty https://investors.atarabio.com/news-events/press-releases/detail/302/atara-biotherapeutics-announces-changes-to-its-board-of https://investors.atarabio.com/news-events/press-releases/detail/301/atara-biotherapeutics-ebvallo-tabelecleucel https://investors.atarabio.com/news-events/press-releases/detail/300/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/299/atara-biotherapeutics-presents-updated-clinical-data-from https://investors.atarabio.com/news-events/press-releases/detail/298/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/297/atara-biotherapeutics-to-participate-at-the-evercore-isi https://investors.atarabio.com/news-events/press-releases/detail/296/atara-biotherapeutics-to-participate-at-the-stifel https://investors.atarabio.com/news-events/press-releases/detail/295/atara-biotherapeutics-announces-third-quarter-2022 https://investors.atarabio.com/news-events/press-releases/detail/294/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/293/atara-biotherapeutics-to-announce-third-quarter-2022 https://investors.atarabio.com/news-events/press-releases/detail/292/atara-biotherapeutics-presents-new-mri-and-updated https://investors.atarabio.com/news-events/press-releases/detail/291/chmp-recommends-approval-of-atara-biotherapeutics https://investors.atarabio.com/news-events/press-releases/detail/290/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/289/atara-biotherapeutics-to-receive-additional-near-term https://investors.atarabio.com/news-events/press-releases/detail/288/atara-biotherapeutics-to-participate-in-cell-therapy-panel https://investors.atarabio.com/news-events/press-releases/detail/287/atara-biotherapeutics-announces-second-quarter-2022 https://investors.atarabio.com/news-events/press-releases/detail/286/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/285/atara-biotherapeutics-to-present-at-the-canaccord-genuity https://investors.atarabio.com/news-events/press-releases/detail/284/atara-biotherapeutics-to-announce-second-quarter-2022 https://investors.atarabio.com/news-events/press-releases/detail/283/atara-biotherapeutics-announces-completion-of-the-ata188 https://investors.atarabio.com/news-events/press-releases/detail/282/atara-biotherapeutics-to-announce-completion-of-ata188 https://investors.atarabio.com/news-events/press-releases/detail/281/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/280/atara-biotherapeutics-announces-first-clinical-data-from https://investors.atarabio.com/news-events/press-releases/detail/279/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/278/atara-biotherapeutics-provides-update-on-strategic https://investors.atarabio.com/news-events/press-releases/detail/277/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/276/atara-biotherapeutics-announces-first-quarter-2022 https://investors.atarabio.com/news-events/press-releases/detail/275/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/274/atara-biotherapeutics-to-announce-first-quarter-2022 https://investors.atarabio.com/news-events/press-releases/detail/273/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/272/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/271/atara-biotherapeutics-names-biopharmaceutical-executive https://investors.atarabio.com/news-events/press-releases/detail/270/atara-biotherapeutics-announces-the-completion-of-the https://investors.atarabio.com/news-events/press-releases/detail/269/atara-biotherapeutics-to-host-ebv-and-ms-day https://investors.atarabio.com/news-events/press-releases/detail/268/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/267/atara-biotherapeutics-to-participate-in-cell-therapy-panel https://investors.atarabio.com/news-events/press-releases/detail/266/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/265/atara-biotherapeutics-provides-update-on-ata2271-autologous https://investors.atarabio.com/news-events/press-releases/detail/264/atara-biotherapeutics-to-announce-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/263/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/262/atara-biotherapeutics-enters-strategic-manufacturing https://investors.atarabio.com/news-events/press-releases/detail/261/new-landmark-nature-study-provides-long-sought-mechanistic https://investors.atarabio.com/news-events/press-releases/detail/260/atara-biotherapeutics-to-present-recent-progress-and-key https://investors.atarabio.com/news-events/press-releases/detail/259/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/258/atara-biotherapeutics-to-present-at-the-40th-annual-j-p https://investors.atarabio.com/news-events/press-releases/detail/257/atara-biotherapeutics-announces-positive-results-from https://investors.atarabio.com/news-events/press-releases/detail/256/atara-biotherapeutics-announces-preliminary-results-for https://investors.atarabio.com/news-events/press-releases/detail/255/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/254/european-medicines-agency-ema-validates-atara https://investors.atarabio.com/news-events/press-releases/detail/253/atara-biotherapeutics-to-participate-at-three-upcoming https://investors.atarabio.com/news-events/press-releases/detail/252/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/251/atara-biotherapeutics-to-present-eight-abstracts-at-the https://investors.atarabio.com/news-events/press-releases/detail/250/atara-biotherapeutics-announces-third-quarter-2021 https://investors.atarabio.com/news-events/press-releases/detail/249/atara-biotherapeutics-to-announce-third-quarter-2021 https://investors.atarabio.com/news-events/press-releases/detail/248/atara-biotherapeutics-presents-new-magnetization-transfer https://investors.atarabio.com/news-events/press-releases/detail/247/atara-biotherapeutics-and-pierre-fabre-enter-strategic https://investors.atarabio.com/news-events/press-releases/detail/246/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/245/atara-biotherapeutics-to-present-phase-1-study-update-of https://investors.atarabio.com/news-events/press-releases/detail/244/european-medicines-agency-grants-atara-biotherapeutics https://investors.atarabio.com/news-events/press-releases/detail/243/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/242/atara-biotherapeutics-to-participate-in-a-panel-discussion https://investors.atarabio.com/news-events/press-releases/detail/241/atara-biotherapeutics-announces-second-quarter-2021 https://investors.atarabio.com/news-events/press-releases/detail/240/atara-biotherapeutics-appoints-cell-therapy-and-oncology https://investors.atarabio.com/news-events/press-releases/detail/239/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/238/atara-biotherapeutics-to-announce-second-quarter-2021 https://investors.atarabio.com/news-events/press-releases/detail/237/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/236/atara-biotherapeutics-joins-the-rare-disease-company https://investors.atarabio.com/news-events/press-releases/detail/235/atara-biotherapeutics-presents-positive-tab-cel-long-term https://investors.atarabio.com/news-events/press-releases/detail/234/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/233/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/232/atara-biotherapeutics-to-participate-at-the-cowen-virtual https://investors.atarabio.com/news-events/press-releases/detail/231/atara-biotherapeutics-names-cell-therapy-oncology-leader https://investors.atarabio.com/news-events/press-releases/detail/230/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/229/atara-biotherapeutics-announces-first-quarter-2021 https://investors.atarabio.com/news-events/press-releases/detail/228/atara-biotherapeutics-to-announce-first-quarter-2021 https://investors.atarabio.com/news-events/press-releases/detail/227/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/226/atara-biotherapeutics-presents-new-long-term-overall https://investors.atarabio.com/news-events/press-releases/detail/225/atara-biotherapeutics-to-participate-in-virtual-33rd-annual https://investors.atarabio.com/news-events/press-releases/detail/224/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/223/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/222/atara-biotherapeutics-to-announce-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/221/atara-biotherapeutics-presents-key-data-for-advancing-the https://investors.atarabio.com/news-events/press-releases/detail/220/atara-biotherapeutics-to-present-data-at-the-2021 https://investors.atarabio.com/news-events/press-releases/detail/219/atara-biotherapeutics-will-present-recent-advancements-and https://investors.atarabio.com/news-events/press-releases/detail/218/atara-biotherapeutics-to-present-at-the-39th-annual-j-p https://investors.atarabio.com/news-events/press-releases/detail/217/atara-biotherapeutics-provides-regulatory-update-for https://investors.atarabio.com/news-events/press-releases/detail/216/atara-biotherapeutics-announces-pricing-of-175-0-million https://investors.atarabio.com/news-events/press-releases/detail/215/atara-biotherapeutics-announces-proposed-offering-of-common https://investors.atarabio.com/news-events/press-releases/detail/214/atara-biotherapeutics-presents-first-preclinical-evaluation https://investors.atarabio.com/news-events/press-releases/detail/213/bayer-and-atara-biotherapeutics-enter-strategic https://investors.atarabio.com/news-events/press-releases/detail/212/atara-biotherapeutics-to-participate-at-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/211/atara-biotherapeutics-to-present-new-open-label-extension https://investors.atarabio.com/news-events/press-releases/detail/210/atara-biotherapeutics-presents-new-preclinical-data-on https://investors.atarabio.com/news-events/press-releases/detail/209/atara-biotherapeutics-announces-third-quarter-2020 https://investors.atarabio.com/news-events/press-releases/detail/208/atara-biotherapeutics-to-announce-third-quarter-2020 https://investors.atarabio.com/news-events/press-releases/detail/207/atara-biotherapeutics-to-present-clinical-data-in https://investors.atarabio.com/news-events/press-releases/detail/206/atara-biotherapeutics-announces-all-progressive-multiple https://investors.atarabio.com/news-events/press-releases/detail/205/atara-biotherapeutics-announces-fda-clearance-of-ind-for https://investors.atarabio.com/news-events/press-releases/detail/204/atara-biotherapeutics-to-present-12-month-data-from-all https://investors.atarabio.com/news-events/press-releases/detail/203/atara-biotherapeutics-announces-second-quarter-2020 https://investors.atarabio.com/news-events/press-releases/detail/202/atara-biotherapeutics-to-announce-second-quarter-2020 https://investors.atarabio.com/news-events/press-releases/detail/201/atara-biotherapeutics-announces-full-exercise-of https://investors.atarabio.com/news-events/press-releases/detail/200/atara-biotherapeutics-announces-first-patient-enrolled-in https://investors.atarabio.com/news-events/press-releases/detail/199/atara-biotherapeutics-announces-its-2020-annual-meeting-of https://investors.atarabio.com/news-events/press-releases/detail/198/atara-biotherapeutics-to-participate-at-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/197/atara-biotherapeutics-announces-pricing-of-175-5-million https://investors.atarabio.com/news-events/press-releases/detail/196/atara-biotherapeutics-announces-proposed-offering-of-common https://investors.atarabio.com/news-events/press-releases/detail/195/atara-biotherapeutics-presents-data-demonstrating-safety https://investors.atarabio.com/news-events/press-releases/detail/194/atara-biotherapeutics-to-present-late-breaking-ata188-data https://investors.atarabio.com/news-events/press-releases/detail/193/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/192/atara-biotherapeutics-announces-presentation-of https://investors.atarabio.com/news-events/press-releases/detail/191/atara-biotherapeutics-names-cell-therapy-oncology-leader https://investors.atarabio.com/news-events/press-releases/detail/190/atara-biotherapeutics-announces-appointment-of-cell-gene https://investors.atarabio.com/news-events/press-releases/detail/189/atara-biotherapeutics-announces-first-quarter-2020 https://investors.atarabio.com/news-events/press-releases/detail/188/atara-biotherapeutics-to-announce-first-quarter-2020 https://investors.atarabio.com/news-events/press-releases/detail/187/atara-biotherapeutics-appoints-biotech-and-finance-industry https://investors.atarabio.com/news-events/press-releases/detail/186/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/184/atara-biotherapeutics-provides-update-in-context-of https://investors.atarabio.com/news-events/press-releases/detail/183/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/182/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/181/atara-biotherapeutics-to-participate-at-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/180/atara-biotherapeutics-to-announce-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/179/atara-biotherapeutics-names-kristin-yarema-as-chief https://investors.atarabio.com/news-events/press-releases/detail/178/atara-biotherapeutics-to-present-2020-key-milestones-and https://investors.atarabio.com/news-events/press-releases/detail/177/atara-biotherapeutics-reports-updated-long-term-clinical https://investors.atarabio.com/news-events/press-releases/detail/176/atara-biotherapeutics-to-participate-at-evercore-isi-second https://investors.atarabio.com/news-events/press-releases/detail/175/atara-biotherapeutics-announces-third-quarter-2019 https://investors.atarabio.com/news-events/press-releases/detail/174/atara-biotherapeutics-to-present-tab-cel-long-term https://investors.atarabio.com/news-events/press-releases/detail/173/atara-biotherapeutics-to-announce-third-quarter-2019 https://investors.atarabio.com/news-events/press-releases/detail/172/atara-biotherapeutics-announces-executive-departures https://investors.atarabio.com/news-events/press-releases/detail/171/atara-biotherapeutics-to-present-initial-efficacy-and https://investors.atarabio.com/news-events/press-releases/detail/170/atara-biotherapeutics-to-participate-in-citi-14th-annual https://investors.atarabio.com/news-events/press-releases/detail/169/atara-biotherapeutics-announces-second-quarter-2019 https://investors.atarabio.com/news-events/press-releases/detail/168/atara-biotherapeutics-to-announce-second-quarter-2019 https://investors.atarabio.com/news-events/press-releases/detail/167/atara-biotherapeutics-announces-pricing-of-150-0-million https://investors.atarabio.com/news-events/press-releases/detail/166/atara-biotherapeutics-announces-proposed-offering-of-common https://investors.atarabio.com/news-events/press-releases/detail/165/atara-biotherapeutics-announces-plan-to-initiate-tab-cel https://investors.atarabio.com/news-events/press-releases/detail/164/atara-biotherapeutics-presents-initial-ata188-phase-1 https://investors.atarabio.com/news-events/press-releases/detail/163/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/162/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/161/atara-biotherapeutics-announces-collaborator-presentation https://investors.atarabio.com/news-events/press-releases/detail/160/atara-biotherapeutics-presents-tab-cel-clinical-biomarker https://investors.atarabio.com/news-events/press-releases/detail/159/atara-biotherapeutics-to-participate-at-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/158/atara-biotherapeutics-appoints-pascal-touchon-president https://investors.atarabio.com/news-events/press-releases/detail/157/atara-biotherapeutics-announces-presentations-highlighting https://investors.atarabio.com/news-events/press-releases/detail/156/atara-biotherapeutics-announces-presentation-of-initial https://investors.atarabio.com/news-events/press-releases/detail/155/atara-biotherapeutics-announces-first-quarter-2019 https://investors.atarabio.com/news-events/press-releases/detail/154/atara-biotherapeutics-to-announce-first-quarter-2019 https://investors.atarabio.com/news-events/press-releases/detail/153/atara-biotherapeutics-presents-off-the-shelf-allogeneic https://investors.atarabio.com/news-events/press-releases/detail/152/atara-biotherapeutics-announces-collaborator-presentation https://investors.atarabio.com/news-events/press-releases/detail/151/atara-biotherapeutics-to-participate-in-upcoming-conferences https://investors.atarabio.com/news-events/press-releases/detail/150/atara-biotherapeutics-announces-presentations-highlighting https://investors.atarabio.com/news-events/press-releases/detail/149/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/148/atara-biotherapeutics-to-participate-in-the-37th-annual https://investors.atarabio.com/news-events/press-releases/detail/147/atara-biotherapeutics-announces-planned-chief-executive https://investors.atarabio.com/news-events/press-releases/detail/146/atara-biotherapeutics-exclusively-licenses https://investors.atarabio.com/news-events/press-releases/detail/145/atara-biotherapeutics-presents-positive-efficacy-and-safety https://investors.atarabio.com/news-events/press-releases/detail/144/atara-biotherapeutics-announces-next-generation-car-t https://investors.atarabio.com/news-events/press-releases/detail/143/atara-biotherapeutics-highlights-next-generation-and https://investors.atarabio.com/news-events/press-releases/detail/142/atara-biotherapeutics-to-host-car-t-breakfast-teach-in-on https://investors.atarabio.com/news-events/press-releases/detail/141/atara-biotherapeutics-announces-publication-of-phase-1 https://investors.atarabio.com/news-events/press-releases/detail/140/atara-biotherapeutics-announces-third-quarter-2018 https://investors.atarabio.com/news-events/press-releases/detail/135/atara-biotherapeutics-announces-presentations-highlighting https://investors.atarabio.com/news-events/press-releases/detail/134/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/133/atara-biotherapeutics-appoints-cancer-research-and-clinical https://investors.atarabio.com/news-events/press-releases/detail/132/atara-biotherapeutics-and-moffitt-cancer-center-announce https://investors.atarabio.com/news-events/press-releases/detail/131/atara-biotherapeutics-to-participate-at-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/130/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/129/atara-biotherapeutics-announces-second-quarter-2018 https://investors.atarabio.com/news-events/press-releases/detail/128/atara-biotherapeutics-to-participate-in-the-canaccord https://investors.atarabio.com/news-events/press-releases/detail/127/atara-biotherapeutics-opens-state-of-the-art-operations-and https://investors.atarabio.com/news-events/press-releases/detail/126/atara-biotherapeutics-tab-cel-achieves-positive https://investors.atarabio.com/news-events/press-releases/detail/125/atara-biotherapeutics-announces-publication-of-new-research https://investors.atarabio.com/news-events/press-releases/detail/124/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/123/atara-biotherapeutics-announces-appointment-of-utpal https://investors.atarabio.com/news-events/press-releases/detail/122/atara-biotherapeutics-to-participate-at-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/121/atara-biotherapeutics-to-present-long-term-tab-cel-phase https://investors.atarabio.com/news-events/press-releases/detail/120/atara-biotherapeutics-announces-first-quarter-2018 https://investors.atarabio.com/news-events/press-releases/detail/119/atara-biotherapeutics-expands-t-cell-immunotherapy https://investors.atarabio.com/news-events/press-releases/detail/118/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/117/biotech-industry-veteran-dietmar-berger-m-d-ph-d-joins https://investors.atarabio.com/news-events/press-releases/detail/116/atara-biotherapeutics-expands-commercial-leadership-team https://investors.atarabio.com/news-events/press-releases/detail/115/atara-biotherapeutics-reports-inducement-grants-under https://investors.atarabio.com/news-events/press-releases/detail/114/atara-biotherapeutics-to-participate-in-three-upcoming https://investors.atarabio.com/news-events/press-releases/detail/113/atara-biotherapeutics-to-present-at-the-44th-annual-meeting https://investors.atarabio.com/news-events/press-releases/detail/112/atara-biotherapeutics-to-present-at-the-cowen-and-company https://investors.atarabio.com/news-events/press-releases/detail/111/atara-biotherapeutics-announces-pricing-of-public-offering https://investors.atarabio.com/news-events/press-releases/detail/110/atara-biotherapeutics-announces-proposed-offering-of-common https://investors.atarabio.com/news-events/press-releases/detail/109/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/108/atara-biotherapeutics-announces-chief-financial-officer https://investors.atarabio.com/news-events/press-releases/detail/107/atara-biotherapeutics-announces-fda-clearance-to-proceed https://investors.atarabio.com/news-events/press-releases/detail/106/atara-biotherapeutics-announces-pricing-of-public-offering https://investors.atarabio.com/news-events/press-releases/detail/105/atara-biotherapeutics-announces-proposed-offering-of-common https://investors.atarabio.com/news-events/press-releases/detail/104/atara-biotherapeutics-announces-initiation-of-two-phase-3 https://investors.atarabio.com/news-events/press-releases/detail/103/atara-biotherapeutics-announces-fda-clearance-to-initiate https://investors.atarabio.com/news-events/press-releases/detail/102/atara-biotherapeutics-to-host-corporate-update-conference https://investors.atarabio.com/news-events/press-releases/detail/101/atara-biotherapeutics-announces-updated-positive-interim https://investors.atarabio.com/news-events/press-releases/detail/100/atara-biotherapeutics-announces-third-quarter-2017 https://investors.atarabio.com/news-events/press-releases/detail/99/atara-biotherapeutics-to-participate-in-four-upcoming https://investors.atarabio.com/news-events/press-releases/detail/98/atara-biotherapeutics-announces-two-presentations-at-59th https://investors.atarabio.com/news-events/press-releases/detail/97/atara-biotherapeutics-receives-rare-pediatric-disease https://investors.atarabio.com/news-events/press-releases/detail/96/atara-biotherapeutics-announces-six-of-ten-progressive https://investors.atarabio.com/news-events/press-releases/detail/95/atara-biotherapeutics-initiates-60-patient-global-phase-1 https://investors.atarabio.com/news-events/press-releases/detail/94/atara-biotherapeutics-announces-abstract-publication-for https://investors.atarabio.com/news-events/press-releases/detail/93/atara-biotherapeutics-receives-positive-health-canada https://investors.atarabio.com/news-events/press-releases/detail/92/atara-biotherapeutics-receives-fda-orphan-drug-designation https://investors.atarabio.com/news-events/press-releases/detail/91/atara-biotherapeutics-to-participate-in-three-upcoming https://investors.atarabio.com/news-events/press-releases/detail/90/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/89/atara-biotherapeutics-expands-leadership-team-with-the https://investors.atarabio.com/news-events/press-releases/detail/88/atara-biotherapeutics-announces-second-quarter-2017 https://investors.atarabio.com/news-events/press-releases/detail/87/atara-biotherapeutics-to-present-at-the-canaccord-genuity https://investors.atarabio.com/news-events/press-releases/detail/86/atara-biotherapeutics-announces-two-presentations-at https://investors.atarabio.com/news-events/press-releases/detail/85/atara-biotherapeutics-to-present-at-three-upcoming-investor https://investors.atarabio.com/news-events/press-releases/detail/84/atara-biotherapeutics-reports-inducement-grant-under-nasdaq https://investors.atarabio.com/news-events/press-releases/detail/83/atara-biotherapeutics-enhances-commercial-expertise-with https://investors.atarabio.com/news-events/press-releases/detail/82/atara-biotherapeutics-announces-first-quarter-2017 https://investors.atarabio.com/news-events/press-releases/detail/81/atara-bio-announces-collaboration-with-merck-to-evaluate https://investors.atarabio.com/news-events/press-releases/detail/80/atara-bio-announces-positive-interim-results-from-ongoing https://investors.atarabio.com/news-events/press-releases/detail/79/atara-bio-expands-management-team-appoints-joe-newell-as https://investors.atarabio.com/news-events/press-releases/detail/78/atara-bios-collaborating-investigators-to-present-interim https://investors.atarabio.com/news-events/press-releases/detail/77/atara-bio-announces-fourth-quarter-and-full-year-2016 https://investors.atarabio.com/news-events/press-releases/detail/76/atara-bio-to-present-at-the-35th-annual-j-p-morgan https://investors.atarabio.com/news-events/press-releases/detail/75/atara-bio-concludes-ema-scientific-advice-and-plans-to https://investors.atarabio.com/news-events/press-releases/detail/74/atara-bio-reaches-agreement-with-fda-on-design-of-phase-3 https://investors.atarabio.com/news-events/press-releases/detail/73/atara-bio-announces-results-from-ongoing-phase-2-trial-of https://investors.atarabio.com/news-events/press-releases/detail/72/atara-bio-announces-third-quarter-2016-financial-results https://investors.atarabio.com/news-events/press-releases/detail/71/atara-bios-collaborating-investigators-to-present-results https://investors.atarabio.com/news-events/press-releases/detail/70/atara-bio-granted-access-to-priority-medicines-prime https://investors.atarabio.com/news-events/press-releases/detail/69/atara-bio-receives-positive-opinion-from-ema-on-orphan-drug https://investors.atarabio.com/news-events/press-releases/detail/68/atara-bio-to-participate-in-the-morgan-stanley-global https://investors.atarabio.com/news-events/press-releases/detail/67/atara-bio-announces-second-quarter-2016-financial-results https://investors.atarabio.com/news-events/press-releases/detail/66/atara-bio-to-present-at-the-canaccord-genuity-36th-annual https://investors.atarabio.com/news-events/press-releases/detail/65/atara-bio-doses-first-patient-in-multi-center-expanded https://investors.atarabio.com/news-events/press-releases/detail/64/atara-bio-receives-advanced-therapy-medicinal-product https://investors.atarabio.com/news-events/press-releases/detail/63/atara-bio-to-present-at-the-jmp-securities-life-sciences https://investors.atarabio.com/news-events/press-releases/detail/62/atara-bio-announces-clinical-trial-results-for-the https://investors.atarabio.com/news-events/press-releases/detail/61/atara-bio-to-present-at-three-upcoming-investor-conferences https://investors.atarabio.com/news-events/press-releases/detail/60/update-new-abstract-links----atara-bio-announces https://investors.atarabio.com/news-events/press-releases/detail/59/atara-bio-announces-presentations-of-clinical-data-from https://investors.atarabio.com/news-events/press-releases/detail/58/atara-bios-collaborating-investigators-to-present https://investors.atarabio.com/news-events/press-releases/detail/57/atara-bio-announces-first-quarter-2016-financial-results https://investors.atarabio.com/news-events/press-releases/detail/56/atara-bios-collaborator-qimr-berghofer-medical-research https://investors.atarabio.com/news-events/press-releases/detail/55/atara-bio-to-present-at-the-15th-annual-needham-healthcare https://investors.atarabio.com/news-events/press-releases/detail/54/atara-bio-announces-participation-in-two-upcoming https://investors.atarabio.com/news-events/press-releases/detail/53/atara-bio-receives-ema-orphan-drug-designation-for https://investors.atarabio.com/news-events/press-releases/detail/52/atara-bio-announces-collaborating-investigators-to-present https://investors.atarabio.com/news-events/press-releases/detail/51/atara-bio-announces-fourth-quarter-and-full-year-2015 https://investors.atarabio.com/news-events/press-releases/detail/50/atara-bio-to-present-at-the-cowen-and-company-36th-annual https://investors.atarabio.com/news-events/press-releases/detail/49/atara-bio-receives-fda-orphan-drug-designation-for-ebv-ctl https://investors.atarabio.com/news-events/press-releases/detail/48/atara-bio-announces-participation-in-two-upcoming-investor https://investors.atarabio.com/news-events/press-releases/detail/47/atara-bio-to-present-at-the-34th-annual-j-p-morgan https://investors.atarabio.com/news-events/press-releases/detail/46/atara-bio-added-to-the-nasdaq-biotechnology-index https://investors.atarabio.com/news-events/press-releases/detail/45/atara-bio-announces-results-from-the-phase-2 https://investors.atarabio.com/news-events/press-releases/detail/44/atara-bio-announces-positive-results-from-a-phase-2 https://investors.atarabio.com/news-events/press-releases/detail/43/atara-bio-announces-positive-results-from-phase-1-clinical https://investors.atarabio.com/news-events/press-releases/detail/42/atara-biotherapeutics-announces-third-quarter-2015 https://investors.atarabio.com/news-events/press-releases/detail/41/atara-bios-collaborating-investigators-to-present-data https://investors.atarabio.com/news-events/press-releases/detail/40/atara-biotherapeutics-announces-participation-in-three https://investors.atarabio.com/news-events/press-releases/detail/39/atara-biotherapeutics-and-qimr-berghofer-medical-research https://investors.atarabio.com/news-events/press-releases/detail/38/atara-bio-receives-fda-orphan-drug-designation-for-stm-434 https://investors.atarabio.com/news-events/press-releases/detail/37/atara-bio-to-host-investor-day-on-october-21-2015 https://investors.atarabio.com/news-events/press-releases/detail/36/atara-bios-pinta-745-improves-insulin-sensitivity-and https://investors.atarabio.com/news-events/press-releases/detail/35/atara-bios-collaborating-investigators-to-present-data https://investors.atarabio.com/news-events/press-releases/detail/34/atara-bios-t-cell-product-candidate-activated-against https://investors.atarabio.com/news-events/press-releases/detail/33/atara-biotherapeutics-inc-to-present-at-upcoming-investor https://investors.atarabio.com/news-events/press-releases/detail/32/atara-biotherapeutics-announces-completion-of-enrollment-in https://investors.atarabio.com/news-events/press-releases/detail/31/atara-biotherapeutics-announces-second-quarter-2015-results https://investors.atarabio.com/news-events/press-releases/detail/30/atara-bio-announces-closing-of-underwritten-offering-of https://investors.atarabio.com/news-events/press-releases/detail/29/atara-bio-announces-pricing-of-its-180-0-million-offering https://investors.atarabio.com/news-events/press-releases/detail/28/atara-bio-announces-proposed-offering-of-common-stock https://investors.atarabio.com/news-events/press-releases/detail/27/atara-biotherapeutics-exercises-exclusive-license-to-t-cell https://investors.atarabio.com/news-events/press-releases/detail/26/atara-biotherapeutics-inc-to-present-at-upcoming-investor https://investors.atarabio.com/news-events/press-releases/detail/25/update-atara-biotherapeutics-collaborating-investigators https://investors.atarabio.com/news-events/press-releases/detail/24/atara-biotherapeutics-collaborating-investigators-to https://investors.atarabio.com/news-events/press-releases/detail/23/atara-biotherapeutics-inc-to-present-at-the-ubs-global https://investors.atarabio.com/news-events/press-releases/detail/22/atara-biotherapeutics-announces-first-quarter-2015-results https://investors.atarabio.com/news-events/press-releases/detail/21/ebv-ctl-clinical-trial-data-presented-by-atara https://investors.atarabio.com/news-events/press-releases/detail/20/atara-biotherapeutics-collaborating-investigators https://investors.atarabio.com/news-events/press-releases/detail/19/atara-biotherapeutics-inc-to-present-at-the-2015 https://investors.atarabio.com/news-events/press-releases/detail/18/atara-biotherapeutics-inc-to-present-at-the-needham https://investors.atarabio.com/news-events/press-releases/detail/14/atara-biotherapeutics-inc-appoints-eric-dobmeier-chief https://investors.atarabio.com/news-events/press-releases/detail/17/atara-biotherapeutics-collaborating-investigators-to https://investors.atarabio.com/news-events/press-releases/detail/15/atara-biotherapeutics-names-david-a-carmel-as-head-of https://investors.atarabio.com/news-events/press-releases/detail/16/fda-grants-breakthrough-therapy-designation-to-epstein-barr https://investors.atarabio.com/news-events/press-releases/detail/12/atara-biotherapeutics-announces-fourth-quarter-and-full https://investors.atarabio.com/news-events/press-releases/detail/13/atara-biotherapeutics-announces-closing-of-underwritten https://investors.atarabio.com/news-events/press-releases/detail/11/atara-bio-announces-pricing-of-its-65-5-million-offering https://investors.atarabio.com/news-events/press-releases/detail/10/atara-bio-announces-proposed-offering-of-common-stock https://investors.atarabio.com/news-events/press-releases/detail/9/atara-to-present-at-the-j-p-morgan-healthcare-conference https://investors.atarabio.com/news-events/press-releases/detail/7/atara-biotherapeutics-announces-third-quarter-2014 https://investors.atarabio.com/news-events/press-releases/detail/8/atara-biotherapeutics-collaborating-investigators-to https://investors.atarabio.com/news-events/press-releases/detail/6/atara-biotherapeutics-doses-first-patient-in-phase-1 https://investors.atarabio.com/news-events/press-releases/detail/5/atara-biotherapeutics-announces-pricing-of-its-initial https://investors.atarabio.com/news-events/press-releases/detail/139/atara-biotherapeutics-announces-immunotherapy-alliance-with https://investors.atarabio.com/news-events/press-releases/detail/138/atara-biotherapeutics-strengthens-board-and-senior https://investors.atarabio.com/news-events/press-releases/detail/137/atara-biotherapeutics-announces-second-closing-of-52 https://investors.atarabio.com/news-events/press-releases/detail/136/atara-biotherapeutics-secures-38-5-million-series-b https://investors.atarabio.com/privacy-policy https://investors.atarabio.com/disclaimer https://investors.atarabio.com/sitemap